Doctors welcome return of diabetes drug - pioglitazone | chandigarh | Hindustan Times
Today in New Delhi, India
Sep 26, 2017-Tuesday
-°C
New Delhi
  • Humidity
    -
  • Wind
    -

Doctors welcome return of diabetes drug - pioglitazone

Diabetic patients taking pioglitazone can breathe easy with the revoke over the ban order on the drug, say doctors welcoming the decision. According to experts, there are more than 6 crore diabetic patients in India, most of who take some medication. "Over 30 lakh diabetics in India take pioglitazone due to the drug's favourable mechanism of action," says Dr KP Singh.

chandigarh Updated: Aug 14, 2013 19:35 IST
HT Correspondent

Diabetic patients taking pioglitazone can breathe easy with the revoke over the ban order on the drug, say doctors welcoming the decision. According to experts, there are more than 6 crore diabetic patients in India, most of who take some medication. "Over 30 lakh diabetics in India take pioglitazone due to the drug's favourable mechanism of action," says Dr KP Singh.

According to Dr Singh, the health ministry consulted the Drug Testing Advisory Board (DTAB) and experts in diabetes to come to a conclusion that pioglitazone if used appropriately in the right type of patients is effective and safe, and it has an integral place in the treatment therapy of type 2 diabetes.

Healthcare professionals have and will be informed of the conditions or type of patients in whom pioglitazone should be avoided, he adds.

Significantly, pioglitazone remains among the most efficacious and economical type- 2 diabetic drugs in the market and patients should consult their doctors for any queries. In general, doctors prescribe the drug only after knowing the patient's history and eligibility of the drug for the particular patient.

According to experts, pioglitazone improves blood sugar levels in people with type-2 diabetes by increasing reactivity of one's body to insulin, which makes it an important prescription choice for doctors. It is an economical alternative to insulin and one of the cost-effective treatments for diabetes.

Fast facts about Pioglitazone
US FDA approved pioglitazone for the treatment of type-2 diabetes mellitus in 1999
Used as a second or third-line treatment

Insulin resistance is more common in Asian Indians and hence glitazones have been very popular in India
* In India, costs are low; Rs 1-4 per tablet